OpenLegislation

Division 3.2.1 Introduction: finished product, active substance and starting materialsF1F2

United Kingdom

Original text. Later amendments are not shown.

  1. 3.2.1.1Gene therapy medicinal product containing recombinant nucleic acid sequence(s) or genetically modified microorganism(s) or virus(es)
  2. 3.2.1.2Gene therapy medicinal product containing genetically modified cells
  3. 3.2.1.3Division 3.2.1.3
  4. 3.2.1.4Division 3.2.1.4
  5. 3.2.1.5Division 3.2.1.5

Annotations

Textual amendments

F1

Substituted by Commission directive 2003/63/EC of 25 June 2003 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use (Text with EEA relevance).

F2

Substituted by Commission Directive 2009/120/EC of 14 September 2009 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use as regards advanced therapy medicinal products (Text with EEA relevance).